Literature DB >> 22674346

Primary cancers before and after prostate cancer diagnosis.

Mieke Van Hemelrijck1, Linda Drevin, Lars Holmberg, Hans Garmo, Jan Adolfsson, Pär Stattin.   

Abstract

BACKGROUND: The occurrence of multiple cancers may indicate common etiology; and, although some studies have investigated the risk of second primary cancers after prostate cancer (PCa), there are no studies on cancers before PCa.
METHODS: The PCBaSe Sweden database is based on the National Prostate Cancer Register (NPCR), which covers >96% of PCa cases. The authors estimated the prevalence and cumulative incidence of different cancers before and after PCa diagnosis in 72,613 men according to PCa treatment and disease stage in PCBaSe and their matched comparison cohort of men who were free of PCa.
RESULTS: In total, 6829 men were diagnosed with another primary cancer before their PCa diagnosis, including 138 men at the time of PCa diagnosis and 5230 men were diagnosed after PCa diagnosis. Cancer of the bladder or colon and nonmelanoma of the skin were the 3 most frequently observed cancers before and after PCa diagnosis. At the time of PCa diagnosis, the prevalence of these 3 cancers was 1.94% for bladder cancer, 1.08% for colon cancer, and 1.08% for nonmelanoma skin cancer, compared with 1.30%, 0.96%, and 1.03%, respectively, for the matched comparison cohort. Five years after PCa diagnosis, the difference in incidence proportion between PCa men and their comparison cohort was 7 ‰ (95% CI, 5.6 ‰-8.5 ‰), 1.3 ‰ (0 ‰-2.6 ‰), and 1.6 ‰ (0.6 ‰-2.6 ‰) for these 3 cancers, respectively. From a uro-oncologic point of view, it is interesting to note that the prevalence of kidney cancer at the time of PCa diagnosis was 0.42% compared with 0.28% for the matched comparison cohort.
CONCLUSIONS: Approximately 17% of all PCa occurred in combination with another primary cancer (before or after PCa diagnosis). Detection bias probably explains part of this observation, but further investigations are required to assess possible underlying mechanisms.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22674346     DOI: 10.1002/cncr.27672

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care.

Authors:  Anthony T Corcoran; Marc C Smaldone; Brian L Egleston; Jay Simhan; Serge Ginzburg; Todd M Morgan; John Walton; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Robert G Uzzo; Alexander Kutikov
Journal:  BJU Int       Date:  2013-07       Impact factor: 5.588

2.  Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma.

Authors:  Kunihisa Nezu; Teppei Okubo; Manabu Shiraiwa; Yoshihiro Nozawa; Atsushi Kyan
Journal:  IJU Case Rep       Date:  2020-08-02

3.  Coupling of prostate and thyroid cancer diagnoses in the United States.

Authors:  Jeffrey J Tomaszewski; Robert G Uzzo; Brian Egleston; Anthony T Corcoran; Reza Mehrazin; Daniel M Geynisman; John A Ridge; Colleen Veloski; Neil Kocher; Marc C Smaldone; Alexander Kutikov
Journal:  Ann Surg Oncol       Date:  2014-09-10       Impact factor: 5.344

4.  Prior-cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate-cancer-specific and all-cause mortality.

Authors:  Kristina Mirabeau-Beale; Ming-Hui Chen; Anthony V D'Amico
Journal:  ISRN Oncol       Date:  2014-01-30

5.  Incidence of second malignancies for prostate cancer.

Authors:  Mieke Van Hemelrijck; Anita Feller; Hans Garmo; Fabio Valeri; Dimitri Korol; Silvia Dehler; Sabine Rohrmann
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

6.  Causes of death in men with localized prostate cancer: a nationwide, population-based study.

Authors:  Mieke Van Hemelrijck; Yasin Folkvaljon; Jan Adolfsson; Olof Akre; Lars Holmberg; Hans Garmo; Pär Stattin
Journal:  BJU Int       Date:  2015-05-15       Impact factor: 5.588

7.  Skin Melanoma and Subsequent Risk of Prostate Cancer: A Lithuanian Cancer Registry Study.

Authors:  Ausvydas Patasius; Vincas Urbonas; Giedre Smailyte
Journal:  Int J Environ Res Public Health       Date:  2019-10-15       Impact factor: 3.390

8.  Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer.

Authors:  Richard Shore; Jingru Yu; Weimin Ye; Jesper Lagergren; Martin Rutegård; Olof Akre; Pär Stattin; Mats Lindblad
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

9.  Prostate cancer patients may have an increased risk of coexisting advanced colorectal neoplasms.

Authors:  Sun-Hye Ko; Myong Ki Baeg; Woong Jin Bae; Pumsoo Kim; Myung-Gyu Choi
Journal:  Onco Targets Ther       Date:  2016-09-09       Impact factor: 4.147

10.  Overall survival and second primary malignancies in men with metastatic prostate cancer.

Authors:  Juha Mehtälä; Jihong Zong; Zdravko Vassilev; Gunnar Brobert; Montse Soriano Gabarró; Pär Stattin; Houssem Khanfir
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.